Acamprol 333 mg: Restoring Neurochemical Balance in Alcohol Dependence
| Product dosage: 333 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.07 | $62.06 (0%) | 🛒 Add to cart |
| 60 | $1.89 | $124.13 $113.11 (9%) | 🛒 Add to cart |
| 90 | $1.42 | $186.19 $128.13 (31%) | 🛒 Add to cart |
| 120 | $1.18 | $248.25 $142.14 (43%) | 🛒 Add to cart |
| 180 | $1.05
Best per pill | $372.38 $188.19 (49%) | 🛒 Add to cart |
Synonyms | |||
Acamprol 333 mg is a specialized pharmacological agent indicated for the maintenance of abstinence in alcohol-dependent patients. Its unique formulation targets key neurotransmitter systems implicated in alcohol craving and withdrawal, offering a non-habit-forming, evidence-based approach to support recovery. By modulating glutamatergic hyperactivity and balancing inhibitory pathways, Acamprol helps reduce the psychological and physiological drive to consume alcohol, making it a cornerstone in comprehensive treatment plans under medical supervision.
Features
- Contains 333 mg of calcium acetylhomotaurinate per enteric-coated tablet
- Delayed-release formulation for optimal gastrointestinal tolerance
- Does not undergo hepatic metabolism; eliminated renally unchanged
- Non-sedating with minimal abuse potential
- Compatible with most psychosocial interventions
- Requires no titration to therapeutic dose in patients with normal renal function
Benefits
- Reduces craving intensity and frequency in alcohol-dependent individuals
- Helps maintain abstinence by decreasing relapse risk
- Minimizes withdrawal-related anxiety and discomfort
- Supports cognitive function restoration during early recovery
- Does not produce euphoria or dependence
- Compatible with long-term maintenance therapy
Common use
Acamprol 333 mg is primarily prescribed for alcohol dependence treatment in patients who have achieved initial abstinence. It is used as part of a comprehensive management program that includes psychosocial support, counseling, and monitoring. The medication is particularly valuable for patients experiencing persistent cravings or those with a history of multiple relapse episodes. Clinical studies demonstrate its efficacy in extending abstinence periods and reducing drinking days when used consistently as directed.
Dosage and direction
The standard adult dosage is two 333 mg tablets taken three times daily (total 1998 mg/day). Tablets should be swallowed whole with water, preferably with meals to enhance gastrointestinal tolerance. Treatment should be initiated as soon as possible after alcohol cessation and typically continues for several months to one year, depending on individual response and clinical assessment. Dosage adjustment is necessary in patients with moderate renal impairment (creatinine clearance 30-50 mL/min): two tablets twice daily. Not recommended in severe renal impairment (creatinine clearance <30 mL/min).
Precautions
Renal function should be assessed before initiation and periodically during treatment. Use with caution in patients with cardiac conditions due to calcium content (approximately 5 mEq calcium per daily dose). May cause gastrointestinal upset; administer with food if tolerated. Not recommended during pregnancy unless potential benefit justifies potential risk. Breastfeeding should be avoided due to unknown excretion in human milk. Elderly patients may require dose adjustment based on renal function. Contains calcium; consider in patients with hypercalcemia or conditions predisposing to hypercalcemia.
Contraindications
Severe renal impairment (creatinine clearance <30 mL/min). Known hypersensitivity to calcium acetylhomotaurinate or any excipients. Patients with hypercalcemia or conditions predisposing to hypercalcemia. Concomitant use with other calcium-containing medications without medical supervision. Not indicated for acute alcohol withdrawal symptoms.
Possible side effects
Most common adverse reactions (>5%) include diarrhea, nausea, abdominal pain, and pruritus. Less frequently reported effects (1-5%) include flatulence, headache, decreased libido, and rash. Rare cases (<1%) of urticaria, elevated liver enzymes, and electrolyte imbalances have been reported. Gastrointestinal symptoms typically diminish with continued use. Most side effects are mild to moderate and transient in nature.
Drug interaction
No clinically significant pharmacokinetic interactions identified. Theoretical potential for reduced absorption when taken with tetracyclines, bisphosphonates, or iron supplements due to calcium content (separate administration by at least 2 hours). May potentiate effects of other CNS-acting substances. No known interactions with disulfiram or naltrexone. Calcium content may interfere with thyroid function tests if performed within 2 hours of administration.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Maintain regular dosing schedule to ensure consistent therapeutic levels. If multiple doses are missed, consult healthcare provider before resuming treatment.
Overdose
Limited data available due to wide therapeutic index. Potential symptoms may include gastrointestinal distress, electrolyte imbalance, or hypercalcemia in susceptible individuals. Treatment should be symptomatic and supportive. Gastric lavage may be considered if ingestion occurred within 1-2 hours. Hemodialysis may be effective due to renal excretion. Contact poison control center for latest management recommendations.
Storage
Store at room temperature (15-30°C) in original container. Protect from moisture and excessive heat. Keep tightly closed. Do not remove desiccant from packaging. Keep out of reach of children and pets. Do not use beyond expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Acamprol 333 mg is available by prescription only and should be used under appropriate medical supervision. Individual response may vary. Healthcare professionals should reference the complete prescribing information before administration. Patients should not adjust dosage without consulting their prescribing physician.
Reviews
Clinical trials demonstrate significant improvement in abstinence rates compared to placebo (p<0.01). Meta-analyses show number needed to treat of 9 for maintaining complete abstinence over 3-6 months. Real-world evidence supports sustained benefit when combined with psychosocial interventions. Patient-reported outcomes indicate improved quality of life measures and reduced craving intensity. Long-term safety profile established through post-marketing surveillance spanning decades.